What:Tyme Technologies Inc. (Nasdaq:TYME), a clinical stage biotechnology company developing novel cancer therapeutics to address multiple tumor types, will visit the Nasdaq MarketSite in Times Square in celebration of their recent IPO.

On Facebook:  https://www.facebook.com/tymetechnologiesOn LinkedIn: https://www.linkedin.com/company-beta/11139295/

In honor of the occasion, Tyme Co-founders Steven Hoffman, CEO & Chief Science Officer, and Michael Demurjian, Chief Operating Officer, will ring the Opening Bell. 

Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:Tuesday, August 8, 2017 – 9:15 a.m. to 9:30 a.m. ET     

Tyme Technologies Inc. Media Contact:James Heins/ICR203-856-2121james.heins@icrinc.com

Nasdaq MarketSite:Emily Pan(646) 441-5120emily.pan@nasdaq.com

Feed Information:Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:http://nasdaq.tumblr.com/

Webcast: A live stream of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.           

About Tyme Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Our lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and we are preparing to initiate an additional Phase II clinical trial for pancreatic cancer. For more information, visit our website: www.tymeinc.com.

About NasdaqNasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

-NDAQA-

Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Nasdaq Charts.
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Nasdaq Charts.